Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clairleaf long-term rollover study of BI 1291583 in bronchiectasis
2023-503290-38-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing BI 1291583 once daily with Placebo once daily (2 arms). Primary endpoint: Occurrence of treatment-emergent adverse events. Planned start Sep 2023; status: authorised.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2023-503290-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503290-38-00.